2023
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M, Petrylak D. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆. Annals Of Oncology 2023, 34: 1047-1054. PMID: 37678672, DOI: 10.1016/j.annonc.2023.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalCarcinoma, Transitional CellDocetaxelHumansUrinary Bladder NeoplasmsConceptsProgression-free survivalEnfortumab vedotinAdverse eventsUrothelial carcinomaTreatment-related adverse event ratesMeaningful overall survival benefitPrior platinum-containing chemotherapyWhite blood cell countEvent ratesAdvanced urothelial carcinomaMetastatic urothelial carcinomaOverall survival benefitPeripheral sensory neuropathyPlatinum-containing chemotherapyNew safety signalsPhase III trialsAdverse event ratesRisk of deathBlood cell countIII trialsMaculopapular rashNeutrophil countObjective responseOverall survivalSurvival benefit
1993
Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer
Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer. Cancer 1993, 71: 1098-1109. PMID: 7679039, DOI: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsBone NeoplasmsCisplatinClinical Trials as TopicCoumarinsDoxorubicinDrug Administration ScheduleDrug ResistanceFluorouracilHumansIntercalating AgentsMaleMethotrexateNeoplasm StagingPolyaminesProstate-Specific AntigenProstatic NeoplasmsRemission InductionSomatostatinConceptsDrug trialsAdvanced hormone-resistant prostate cancerHormone-resistant prostate cancerObjective response rateCombination of vinblastineMost cytotoxic agentsReliable disease markersNew drug trialsProstate cancer cellsCurrent reviewNew therapeutic agentsPartial remissionVisceral metastasesAdvanced adenocarcinomaCytotoxic chemotherapyObjective responseContinuous infusionNonresponsive tumorsMarginal efficacyHormonal manipulationProstate cancerNew agentsResponse rateCytotoxic drugsTherapeutic agents